ICU Medical, Inc. (NASDAQ:ICUI) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. raised its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 9.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 215,808 shares of the medical instruments supplier's stock after acquiring an additional 18,301 shares during the period. Federated Hermes Inc. owned 0.89% of ICU Medical worth $25,627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of ICU Medical by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier's stock valued at $263,226,000 after purchasing an additional 11,991 shares during the period. Schroder Investment Management Group lifted its stake in ICU Medical by 35.8% in the fourth quarter. Schroder Investment Management Group now owns 433,852 shares of the medical instruments supplier's stock valued at $43,272,000 after buying an additional 114,344 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its holdings in shares of ICU Medical by 109.4% in the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier's stock valued at $29,882,000 after acquiring an additional 145,485 shares during the period. WCM Investment Management LLC grew its position in shares of ICU Medical by 5.8% during the first quarter. WCM Investment Management LLC now owns 256,946 shares of the medical instruments supplier's stock worth $27,575,000 after acquiring an additional 14,138 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of ICU Medical by 4.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 220,624 shares of the medical instruments supplier's stock valued at $22,005,000 after acquiring an additional 9,196 shares during the period. Hedge funds and other institutional investors own 96.10% of the company's stock.

Wall Street Analyst Weigh In

ICUI has been the subject of a number of recent research reports. StockNews.com upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Thursday. Raymond James increased their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an "outperform" rating in a research note on Thursday. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research note on Thursday, August 8th. Finally, KeyCorp boosted their target price on ICU Medical from $136.00 to $147.00 and gave the company an "overweight" rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $149.00.

Insiders Place Their Bets

In other news, VP Virginia Ruth Sanzone sold 2,050 shares of ICU Medical stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares in the company, valued at approximately $645,901.02. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the company's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the sale, the vice president now owns 4,482 shares of the company's stock, valued at $645,901.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company's stock, valued at approximately $16,320,691.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,552 shares of company stock worth $4,537,802. Corporate insiders own 6.70% of the company's stock.

ICU Medical Stock Performance

NASDAQ:ICUI traded up $0.51 during mid-day trading on Monday, reaching $179.51. The stock had a trading volume of 295,693 shares, compared to its average volume of 278,686. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The business has a 50 day simple moving average of $144.47 and a 200 day simple moving average of $119.07. ICU Medical, Inc. has a twelve month low of $78.28 and a twelve month high of $181.34. The firm has a market capitalization of $4.37 billion, a price-to-earnings ratio of -73.42 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business had revenue of $596.50 million during the quarter, compared to analysts' expectations of $556.64 million. During the same period last year, the firm earned $1.58 EPS. The company's quarterly revenue was up 8.6% compared to the same quarter last year. On average, analysts expect that ICU Medical, Inc. will post 3.76 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.